Indicated as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.1
Victoza®—a once-daily GLP‑1 RA therapy
Review the Victoza® study data for adult and pediatric patients with T2D
Based on a study designed to quantify the preferences of patients for reducing the frequency of injections with GLP-1 RA from once daily to once weekly. Adult patients with type 2 diabetes (n=643) using once-weekly or once-daily GLP-1 RA injections, or insulin, as well as injection-naïve patients, were surveyed regarding their injection device preferences.3
Ozempic® Important Safety Information
What could your patients who make the change to Ozempic® expect?
On average, patients pay less for Ozempic® compared to Victoza®.b,c
bTo receive the 3-month savings offer, patient must have a 3-month prescription for Ozempic®.
cData based on IQVIA LAAD November 2019 – October 2020.
dData from VANTAGE Fingertip Formulary bridge/October 2020 Nomenclature, and Xponent PlanTrak using week ending 11/6/2020; only considers bridged volume; excludes cash and mail order data; based on full DCS/EDCS/IDCS/HSDCS IC universe (targets and non-targets).
eEligible commercially insured patients with coverage for Ozempic® pay as little as $25 for a 1-month or 3-month supply with the Ozempic® savings offer. Month is defined as 28 days. Maximum savings is $150 for 1-month or $450 for 3-month supply. Offer is good for up to 24 months. Eligibility and restrictions apply.
Patient preference study design3
To quantify the preferences of patients with type 2 diabetes for reducing the frequency of injections with GLP-1 RAs from once daily to once weekly.
A total of 643 adult patients with type 2 diabetes: exenatide QW (n=150), liraglutide QD (n=153), insulin (n=156), and injection naïve (n=184).
A survey was developed to gather and analyze injection device preferences among 4 subgroups that were selected to test whether patients with varying injection experiences would exhibit different preferences: patients taking once-weekly exenatide, patients taking once-daily liraglutide, patients taking insulin, and injection-naïve patients
- Participants chose and ranked, in order of importance, 6 injection device attributes (other than efficacy, safety, or cost) including injection frequency, injection device, needle used to inject, pain associated with injection, need to refrigerate medicine, and bumps or nodules around injection site